Anastasia (Stacy) Henry
@anastasiahenry.bsky.social
Senior Director and Staff Scientist at Denali Therapeutics. My lab is focused on understanding how lysosomal function is perturbed in Parkinson's disease and LSDs.
Reposted by Anastasia (Stacy) Henry
AMP® PDRD is accepting applications from clinical investigators with study cohorts in #Parkinsons or related disorders.
Selected projects will receive fully funded biomarker analyses, at no cost to investigators 🧪
🧠 Apply by November 21, 2025
🔗 See the RFA: bit.ly/49yx7oW
Selected projects will receive fully funded biomarker analyses, at no cost to investigators 🧪
🧠 Apply by November 21, 2025
🔗 See the RFA: bit.ly/49yx7oW
November 12, 2025 at 5:38 PM
AMP® PDRD is accepting applications from clinical investigators with study cohorts in #Parkinsons or related disorders.
Selected projects will receive fully funded biomarker analyses, at no cost to investigators 🧪
🧠 Apply by November 21, 2025
🔗 See the RFA: bit.ly/49yx7oW
Selected projects will receive fully funded biomarker analyses, at no cost to investigators 🧪
🧠 Apply by November 21, 2025
🔗 See the RFA: bit.ly/49yx7oW
Exciting opportunity for clinical researchers in Parkinson’s disease and related disorders: The Accelerating Medicines Partnership in Parkinson’s Disease and Related Disorders (AMP PDRD) is seeking applications for fully-funded biomarker analyses.
Learn more here: lnkd.in/dwFYNy6u
Learn more here: lnkd.in/dwFYNy6u
October 17, 2025 at 2:53 AM
Exciting opportunity for clinical researchers in Parkinson’s disease and related disorders: The Accelerating Medicines Partnership in Parkinson’s Disease and Related Disorders (AMP PDRD) is seeking applications for fully-funded biomarker analyses.
Learn more here: lnkd.in/dwFYNy6u
Learn more here: lnkd.in/dwFYNy6u
New preprint alert! We show that the common GBA1 E326K variant leads to impaired lysosomal delivery of GCase and defects in PD-relevant pathways. Structures of E326K alone and with LIMP2 reveal mechanistic insight. Big thanks to the Vocadlo and Cookson labs!
👉 www.biorxiv.org/content/10.1...
👉 www.biorxiv.org/content/10.1...
A Common PD-Risk GBA1 Variant Disrupts LIMP2 Interaction, Impairs Glucocerebrosidase Function, and Drives Lysosomal and Mitochondrial Dysfunction
Variants in GBA1 cause Gaucher disease (GD), a lysosomal storage disorder, and represent the most common genetic risk factor for Parkinson's disease (PD). While some GBA1 variants are associated with ...
www.biorxiv.org
September 2, 2025 at 3:45 PM
New preprint alert! We show that the common GBA1 E326K variant leads to impaired lysosomal delivery of GCase and defects in PD-relevant pathways. Structures of E326K alone and with LIMP2 reveal mechanistic insight. Big thanks to the Vocadlo and Cookson labs!
👉 www.biorxiv.org/content/10.1...
👉 www.biorxiv.org/content/10.1...
Our new study in Molecular Neurodegeneration shows that LRRK2 kinase activity modulates lysosomal glycosphingolipid and BMP homeostasis. We also report how LRRK2 inhibition alters these biomarkers in LRRK2-PD patients, highlighting their translational potential.
Read more: rdcu.be/ezDU1
Read more: rdcu.be/ezDU1
LRRK2 kinase activity regulates Parkinson’s disease-relevant lipids at the lysosome
rdcu.be
August 7, 2025 at 7:44 PM
Our new study in Molecular Neurodegeneration shows that LRRK2 kinase activity modulates lysosomal glycosphingolipid and BMP homeostasis. We also report how LRRK2 inhibition alters these biomarkers in LRRK2-PD patients, highlighting their translational potential.
Read more: rdcu.be/ezDU1
Read more: rdcu.be/ezDU1
🚨New job post alert 🚨
We are looking to recruit a talented in vivo scientist to support our growing Parkinson's disease portfolio. Please reach out if you are interested in learning more!
www.denalitherapeutics.com/job?id=0844a...
We are looking to recruit a talented in vivo scientist to support our growing Parkinson's disease portfolio. Please reach out if you are interested in learning more!
www.denalitherapeutics.com/job?id=0844a...
Job
Denali Therapeutics is dedicated to defeating neurodegenerative diseases through rigorous therapeutic discovery and development.
www.denalitherapeutics.com
January 16, 2025 at 5:48 PM
🚨New job post alert 🚨
We are looking to recruit a talented in vivo scientist to support our growing Parkinson's disease portfolio. Please reach out if you are interested in learning more!
www.denalitherapeutics.com/job?id=0844a...
We are looking to recruit a talented in vivo scientist to support our growing Parkinson's disease portfolio. Please reach out if you are interested in learning more!
www.denalitherapeutics.com/job?id=0844a...
Excited to share that dosing has begun in the Denali Phase 2a "BEACON" study of the investigational therapeutic BIIB122 in Parkinson's disease patients that carry a variant in LRRK2!
investors.denalitherapeutics.com/news-release...
investors.denalitherapeutics.com/news-release...
Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of LRRK2 Inhibitor, BIIB122, in LRRK2-Associated Parkinson’s Disease | Denali Therapeutics
The Investor Relations website contains information about Denali Therapeutics's business for stockholders, potential investors, and financial analysts.
investors.denalitherapeutics.com
December 5, 2024 at 8:07 PM
Excited to share that dosing has begun in the Denali Phase 2a "BEACON" study of the investigational therapeutic BIIB122 in Parkinson's disease patients that carry a variant in LRRK2!
investors.denalitherapeutics.com/news-release...
investors.denalitherapeutics.com/news-release...
Interested in doing an internship in industry exploring the mechanisms of lysosomal dysfunction associated with PD? Here's a great opportunity to work with an outstanding scientist in my team!
dnli.wd1.myworkdayjobs.com/Internships/...
dnli.wd1.myworkdayjobs.com/Internships/...
Intern, Pathway Biology
Neurodegenerative diseases are one of the largest medical challenges of our time. Denali Therapeutics is a biotechnology company dedicated to developing breakthrough therapies for neurodegenerative di...
dnli.wd1.myworkdayjobs.com
November 25, 2024 at 8:30 PM
Interested in doing an internship in industry exploring the mechanisms of lysosomal dysfunction associated with PD? Here's a great opportunity to work with an outstanding scientist in my team!
dnli.wd1.myworkdayjobs.com/Internships/...
dnli.wd1.myworkdayjobs.com/Internships/...
We had a fantastic time collaborating with Ta-Chiang Liu and his team to assess the role of LRRK2 activity in Paneth cell dysfunction linked to Crohn's disease. Our paper is now out in Science Immunology!
www.science.org/doi/10.1126/...
www.science.org/doi/10.1126/...
Macrophage LRRK2 hyperactivity impairs autophagy and induces Paneth cell dysfunction
Intestinal macrophage LRRK2 kinase activity impairs Paneth cell function in Crohn’s disease.
www.science.org
November 12, 2024 at 4:52 AM
We had a fantastic time collaborating with Ta-Chiang Liu and his team to assess the role of LRRK2 activity in Paneth cell dysfunction linked to Crohn's disease. Our paper is now out in Science Immunology!
www.science.org/doi/10.1126/...
www.science.org/doi/10.1126/...